Mesoblast Limited (MESO)
NASDAQ: MESO
· Real-Time Price · USD
11.26
-0.79 (-6.56%)
At close: May 05, 2025, 3:59 PM
11.76
4.44%
After-hours: May 05, 2025, 04:32 PM EDT
-6.56% (1D)
| Bid | 9.9 |
| Market Cap | 1.43B |
| Revenue (ttm) | 5.67M |
| Net Income (ttm) | -103.35M |
| EPS (ttm) | -0.94 |
| PE Ratio (ttm) | -11.98 |
| Forward PE | -34.37 |
| Analyst | Buy |
| Ask | 12.05 |
| Volume | 183,367 |
| Avg. Volume (20D) | 268,880 |
| Open | 11.58 |
| Previous Close | 12.05 |
| Day's Range | 11.24 - 11.58 |
| 52-Week Range | 5.78 - 22.00 |
| Beta | 2.03 |
About MESO
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchyma...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 20, 2010
Employees 73
Stock Exchange NASDAQ
Ticker Symbol MESO
Website https://www.mesoblast.com
Analyst Forecast
According to 4 analyst ratings, the average rating for MESO stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 59.86% from the latest price.
Stock Forecasts2 months ago
+4.28%
Mesoblast shares are trading higher after Piper Sa...
Unlock content with
Pro Subscription
4 months ago
+36.82%
Mesoblast shares are trading higher after the company announced the FDA approved Ryoncilas the first mesenchymal stromal cell therapy in the United States.
